Pulmonx CEO sells 56K shares for tax withholding

Pulmonx Corp President and CEO Glendon E. French III reported tax-related share sales.

Rhea-AI Filing Summary

Pulmonx Corp President and CEO Glendon E. French III reported tax-related share sales. On June 1–2, 2026, he sold a total of 56,149 shares of Common Stock at prices around $1.54–$1.57 per share. A footnote explains these shares were sold to cover tax withholding obligations tied to vesting of Restricted Stock Units granted on March 1, 2023, making them compensation-related rather than discretionary trades. After the transactions, he held 1,178,162 shares directly, and a family trust held an additional 918,198 shares indirectly.

Insider Trade Summary

Net Seller: 56,149 shares

Net Sell 4 txns

Insider French Glendon E. III

Role President and CEO

Sold 56,149 shs ($87K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,511	$1.57	$21K
Sale	Common Stock	4,171	$1.54	$6K
Sale	Common Stock	38,467	$1.54	$59K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,178,162 shares (Direct); Common Stock — 918,198 shares (Indirect, By trust)

Footnotes (4)

1. F1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
2. F2. Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of December 1, 2025.
3. F3. Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of June 2, 2025.
4. F4. The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.

Key Figures

Shares sold: 56,149 shares Sale price June 2: $1.57 per share Sale price June 1: $1.54 per share +3 more

6 metrics

Shares sold 56,149 shares Net shares sold over June 1–2, 2026

Sale price June 2 $1.57 per share Open-market sale on June 2, 2026

Sale price June 1 $1.54 per share Open-market sales on June 1, 2026

Direct holdings after trades 1,178,162 shares Common stock held directly after June 2, 2026 transactions

Indirect trust holdings 918,198 shares Common stock held by French Family Revocable Trust

RSU grant date March 1, 2023 RSUs whose vesting triggered tax-withholding sales

Key Terms

Restricted Stock Units, tax withholding obligations, indirect, trustees and beneficiaries

4 terms

Restricted Stock Units financial

"These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units"

indirect financial

"total_shares_following_transaction": "918198.0000", "direct_or_indirect": "I", "nature_of_ownership": "By trust""

trustees and beneficiaries financial

"of which the reporting person and his spouse are trustees and beneficiaries"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pulmonx (LUNG) CEO Glendon French report in this Form 4?

He reported selling 56,149 shares of Pulmonx common stock. The shares were sold around $1.54–$1.57 per share, primarily to cover tax withholding obligations related to vesting of previously granted Restricted Stock Units.

Were the Pulmonx (LUNG) CEO’s share sales open-market trades or tax-related?

The sales were tax-related, not discretionary portfolio trades. A footnote states the shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023.

How many Pulmonx (LUNG) shares did the CEO sell and at what prices?

He sold 56,149 Pulmonx common shares. The reported transactions include sales at about $1.54 and $1.57 per share over June 1–2, 2026, according to the Form 4 filing details.

How many Pulmonx (LUNG) shares does the CEO hold after these transactions?

After the reported sales, he directly held 1,178,162 shares of Pulmonx common stock. A separate holding entry shows an additional 918,198 shares held indirectly through a family trust where he and his spouse are trustees and beneficiaries.

What does the Pulmonx (LUNG) Form 4 say about the CEO’s trust holdings?

The filing notes 918,198 shares are held by the French Family Revocable Trust. A footnote explains Glendon E. French III and his spouse serve as trustees and beneficiaries of this trust, reflecting indirect ownership of those Pulmonx shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

French Glendon E. III

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		4,171	D	$1.54	1,230,140	D
Common Stock	06/01/2026		S(2)		38,467	D	$1.54	1,191,673	D
Common Stock	06/02/2026		S(3)		13,511	D	$1.57	1,178,162	D
Common Stock								918,198	I	By trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.

2. Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of December 1, 2025.

3. Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of June 2, 2025.

4. The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.

	/s/ David Aaron Lehman, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)